NexgenRx Inc. (TSXV:NXG)
Canada · Delayed Price · Currency is CAD 0.6050
0.00 (0.00%)
At close: Aug 25, 2026
NexgenRx Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 18.87 | 17.48 | 15.9 | 13.29 | 12.57 | 11.79 |
Other Revenue | 0.47 | 0.46 | 0.58 | 0.56 | 0.21 | 0.05 |
| 19.34 | 17.93 | 16.48 | 13.85 | 12.78 | 11.84 | |
Revenue Growth | 13.65% | 8.84% | 18.99% | 8.33% | 7.94% | 12.01% |
Cost of Revenue | 2.92 | 3 | 3.35 | 3.03 | 2.6 | 2.03 |
Gross Profit | 16.42 | 14.93 | 13.12 | 10.82 | 10.18 | 9.81 |
Selling, General & Admin | 11.76 | 11.47 | 10.64 | 9.62 | 8.43 | 6.18 |
Amortization of Goodwill & Intangibles | 0.82 | 0.98 | 1.05 | 1.12 | 1.14 | 1.02 |
Operating Expenses | 12.8 | 12.7 | 11.92 | 10.96 | 9.9 | 7.61 |
Operating Income | 3.62 | 2.23 | 1.2 | -0.14 | 0.29 | 2.2 |
Interest Expense | -0.02 | -0.03 | -0.03 | -0.03 | -0.02 | -0.06 |
Other Non Operating Income (Expenses) | -0.15 | -0.15 | -0.14 | -0.13 | -0.13 | -0.13 |
EBT Excluding Unusual Items | 3.44 | 2.06 | 1.03 | -0.31 | 0.13 | 2.01 |
Impairment of Goodwill | -0.16 | -0.16 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.01 | 0.04 | - | - | - | - |
Pretax Income | 3.28 | 1.94 | 1.03 | -0.31 | 0.13 | 2.01 |
Income Tax Expense | 0.65 | 0.65 | 0.41 | 0.03 | 0.16 | -2.01 |
Net Income | 2.63 | 1.29 | 0.61 | -0.33 | -0.02 | 4.02 |
Preferred Dividends & Other Adjustments | 0.26 | 0.23 | 0.2 | 0.2 | - | - |
Net Income to Common | 2.37 | 1.06 | 0.42 | -0.53 | -0.02 | 4.02 |
Net Income Growth | 194.17% | 154.16% | - | - | - | 89.91% |
Shares Outstanding (Basic) | 74 | 71 | 71 | 71 | 70 | 70 |
Shares Outstanding (Diluted) | 77 | 77 | 77 | 71 | 70 | 75 |
Shares Change | -3.03% | 0.68% | 8.51% | 0.28% | -6.01% | 0.88% |
EPS (Basic) | 0.03 | 0.01 | 0.01 | -0.01 | -0.00 | 0.06 |
EPS (Diluted) | 0.03 | 0.01 | 0.01 | -0.01 | -0.00 | 0.05 |
EPS Growth | 206.88% | 180.00% | - | - | - | 86.21% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3.05 | 4.68 | 1.06 | 1.2 | 0.68 | 3.7 |
Free Cash Flow Per Share | 0.04 | 0.06 | 0.01 | 0.02 | 0.01 | 0.05 |
Dividend Per Share | 0.015 | 0.015 | 0.010 | 0.010 | 0.010 | - |
Dividend Growth | 50.00% | 50.00% | 0% | 0% | - | - |
Gross Margin | 84.89% | 83.28% | 79.65% | 78.14% | 79.67% | 82.88% |
Operating Margin | 18.70% | 12.45% | 7.27% | -1.04% | 2.25% | 18.57% |
Profit Margin | 12.23% | 5.90% | 2.53% | -3.83% | -0.18% | 33.93% |
Free Cash Flow Margin | 15.75% | 26.10% | 6.46% | 8.67% | 5.30% | 31.23% |
EBITDA | 3.32 | 2.46 | 1.41 | 0.07 | 1.53 | 3.31 |
EBITDA Margin | 17.18% | 13.72% | 8.53% | 0.49% | 11.98% | 27.98% |
D&A For EBITDA | -0.3 | 0.23 | 0.21 | 0.21 | 1.24 | 1.11 |
EBIT | 3.62 | 2.23 | 1.2 | -0.14 | 0.29 | 2.2 |
EBIT Margin | 18.70% | 12.45% | 7.27% | -1.04% | 2.25% | 18.57% |
Effective Tax Rate | 19.71% | 33.37% | 40.14% | - | 116.66% | - |
Revenue as Reported | 19.34 | 17.93 | 16.48 | 13.85 | 12.78 | 11.84 |